Rate of Rebleed and Retreatment of Previously Treated Intracranial Aneurysms.


Journal

World neurosurgery
ISSN: 1878-8769
Titre abrégé: World Neurosurg
Pays: United States
ID NLM: 101528275

Informations de publication

Date de publication:
04 2021
Historique:
received: 15 11 2020
revised: 13 01 2021
accepted: 13 01 2021
pubmed: 27 1 2021
medline: 23 7 2021
entrez: 26 1 2021
Statut: ppublish

Résumé

Intracranial aneurysms (IAs) can be treated through endovascular treatment (EVT) or microsurgery (MS). Treated IAs can recanalize, which can lead to rupture or retreatment. The aim of our study was to evaluate the natural history of previously treated IA, by evaluating the risk of rupture and the risk of retreatment. All patients treated for an IA between 2007 and 2017 in 4 hospitals were included. The rate of (recurrent) hemorrhage and the rate of prophylactic retreatment were retrospectively evaluated. Kaplan-Meier survival analysis with log-rank tests was used to compare the rates of rupture or retreatment. Patients with ruptured and unruptured aneurysms were separated, and we compared the risk of retreatment between EVT and the surgical treatment. A total of 4997 IAs were included in the study, corresponding to 20,489 patient-years. Overall, 28 (0.6%) aneurysms that had been previously treated demonstrated hemorrhage. Moreover, 237 (4.7%) aneurysms were retreated for recanalization without hemorrhage. The rate of retreatment was higher in the EVT-treated IAs as compared with the MS-treated IAs (LogRank: P < 0.0001) and higher in the previously ruptured IAs versus unruptured IAs (LogRank: P < 0.0001). However, the rate of posttreatment hemorrhage/IA rupture was similar for both groups. The rate of IA retreatment is low; however, the rate of hemorrhage/rupture from treated IAs is even lower. A higher rate of retreatment was noted in EVT-treated IAs versus MS-treated IAs and in ruptured IAs versus unruptured IAs; however, the rate of hemorrhage or rerupture was comparable between the groups.

Sections du résumé

BACKGROUND
Intracranial aneurysms (IAs) can be treated through endovascular treatment (EVT) or microsurgery (MS). Treated IAs can recanalize, which can lead to rupture or retreatment.
OBJECTIVE
The aim of our study was to evaluate the natural history of previously treated IA, by evaluating the risk of rupture and the risk of retreatment.
METHODS
All patients treated for an IA between 2007 and 2017 in 4 hospitals were included. The rate of (recurrent) hemorrhage and the rate of prophylactic retreatment were retrospectively evaluated. Kaplan-Meier survival analysis with log-rank tests was used to compare the rates of rupture or retreatment. Patients with ruptured and unruptured aneurysms were separated, and we compared the risk of retreatment between EVT and the surgical treatment.
RESULTS
A total of 4997 IAs were included in the study, corresponding to 20,489 patient-years. Overall, 28 (0.6%) aneurysms that had been previously treated demonstrated hemorrhage. Moreover, 237 (4.7%) aneurysms were retreated for recanalization without hemorrhage. The rate of retreatment was higher in the EVT-treated IAs as compared with the MS-treated IAs (LogRank: P < 0.0001) and higher in the previously ruptured IAs versus unruptured IAs (LogRank: P < 0.0001). However, the rate of posttreatment hemorrhage/IA rupture was similar for both groups.
CONCLUSIONS
The rate of IA retreatment is low; however, the rate of hemorrhage/rupture from treated IAs is even lower. A higher rate of retreatment was noted in EVT-treated IAs versus MS-treated IAs and in ruptured IAs versus unruptured IAs; however, the rate of hemorrhage or rerupture was comparable between the groups.

Identifiants

pubmed: 33497825
pii: S1878-8750(21)00081-4
doi: 10.1016/j.wneu.2021.01.050
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e650-e657

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Thomas Metayer (T)

Department of Neurosurgery, University Hospital of Caen, Caen, France; Normandie University, Cyceron, France. Electronic address: thomas.metayer@neurochirurgie.fr.

Laura Terrier (L)

Department of Neurosurgery, University Hospital, Rouen, France.

Emmanuel de Schlichting (E)

Department of Neurosurgery, University Hospital, Grenoble, France.

François Lechanoine (F)

Department of Neurosurgery, University Hospital, Grenoble, France.

Nassim Bougaci (N)

Department of Neurosurgery, University Hospital, Nice, France.

Stephane Derrey (S)

Department of Neurosurgery, University Hospital, Rouen, France.

Charlotte Barbier (C)

Department of Neuroradiology, University Hospital of Caen, Caen, France.

Chrysanthi Papagiannaki (C)

Department of Neuroradiology, University Hospital, Rouen, France.

Ahmad Ashraf (A)

Department of Neurosurgery, University Hospital, Grenoble, France.

Florence Tahon (F)

Department of Neuroradiology, University Hospital, Grenoble, France.

Aurelie Leplus (A)

Department of Neurosurgery, University Hospital, Nice, France.

Mikaël Naveau (M)

Normandie University, Cyceron, France; UMS 3408 Cyceron, CNRS, University of Caen Normandy, GIP CYCERON, Caen, France.

Emmanuel Gay (E)

Department of Neurosurgery, University Hospital, Grenoble, France.

Evelyne Emery (E)

Department of Neurosurgery, University Hospital of Caen, Caen, France; Medical School, University of Caen Normandy, Caen, France.

Michel Lonjon (M)

Department of Neurosurgery, University Hospital, Nice, France.

Denis Vivien (D)

Normandie University, Cyceron, France; UMS 3408 Cyceron, CNRS, University of Caen Normandy, GIP CYCERON, Caen, France.

Thomas Gaberel (T)

Department of Neurosurgery, University Hospital of Caen, Caen, France; Normandie University, Cyceron, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH